

## **GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications**

\*Emmanuel Ifeanyi Obeagu<sup>1</sup> and Getrude Uzoma Obeagu<sup>2</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda

<sup>2</sup>School of Nursing Science, Kampala International University, Uganda

\*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

### **Abstract**

Hematological complications, including thrombosis and bleeding disorders, are significant contributors to morbidity and mortality in individuals living with Human Immunodeficiency Virus (HIV) infection. Dysregulation of the coagulation cascade plays a pivotal role in the pathogenesis of these complications. GATA-1, a master transcription factor in hematopoiesis, has emerged as a key regulator of coagulation cascade components and endothelial function. This review explores the multifaceted role of GATA-1 in modulating the coagulation cascade and endothelial function in the context of HIV-associated hematological complications. Insights into the interplay between GATA-1 and the coagulation cascade offer potential targets for therapeutic intervention and may lead to improved management of hematological complications in HIV-infected individuals.

**Keywords:** *GATA-1, coagulation cascade, HIV, hematological complications, thrombosis, bleeding disorders*

### **Introduction**

Hematological complications pose significant challenges in the management of Human Immunodeficiency Virus (HIV) infection, contributing to increased morbidity and mortality in affected individuals. Thrombosis and bleeding disorders represent prominent manifestations of dysregulated coagulation in the context of HIV/AIDS, presenting clinical complexities and

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. Elite Journal of Health Science, 2024; 2(3):45-63

therapeutic dilemmas. The coagulation cascade, comprising a intricate network of proteins and enzymes, orchestrates hemostasis and vascular integrity. However, in HIV-infected individuals, this delicate balance is often disrupted, leading to aberrant thrombotic and bleeding events that pose considerable clinical risks. GATA-1, a master regulator of hematopoiesis, has emerged as a pivotal player in the regulation of the coagulation cascade and endothelial function. Its influence extends beyond hematopoietic cells, encompassing endothelial cells and vascular integrity, thus highlighting its multifaceted role in coagulation homeostasis. Understanding the intricate interplay between GATA-1 and the coagulation cascade is crucial for unraveling the pathogenesis of thrombotic and bleeding complications in HIV-infected individuals. By elucidating the molecular mechanisms underlying GATA-1-mediated coagulation regulation, novel therapeutic targets may be identified to address these hematological challenges.<sup>1-30</sup>

Thrombotic complications, such as venous thromboembolism (VTE) and arterial thrombosis, represent significant contributors to morbidity and mortality in HIV/AIDS. Dysregulated GATA-1 activity may predispose individuals to a prothrombotic state by influencing key components of the coagulation cascade, including tissue factor (TF) expression and platelet function. Additionally, HIV-induced endothelial dysfunction further exacerbates thrombotic risk, underscoring the complex interplay between viral infection, immune dysregulation, and coagulation abnormalities. Conversely, bleeding disorders, including thrombocytopenia and acquired hemophilia, present unique challenges in the management of HIV-related hematological complications. Dysregulated GATA-1 activity may contribute to thrombocytopenia by impairing megakaryopoiesis and platelet function, thereby increasing the risk of bleeding events. Furthermore, alterations in coagulation factor expression and function mediated by GATA-1 dysregulation may lead to acquired hemophilia and exacerbate bleeding tendencies in affected individuals. In light of the significant impact of hematological complications on the clinical course of HIV infection, there is a critical need to elucidate the role of GATA-1 in coagulation regulation and its implications for therapeutic intervention. Targeting GATA-1-mediated pathways may offer novel strategies for managing thrombotic and bleeding complications in HIV-infected individuals, thereby improving clinical outcomes and quality of life. This review aims to explore the multifaceted role of GATA-1 in coagulation cascade regulation within the context of HIV-associated hematological complications, with implications for the development of targeted therapeutic interventions.<sup>31-70</sup>

## **GATA-1 Regulation of Coagulation Cascade**

GATA-1, a key transcription factor in hematopoiesis, exerts significant regulatory control over various components of the coagulation cascade, thereby influencing thrombotic and bleeding tendencies in HIV-infected individuals. Through its intricate regulatory mechanisms, GATA-1 impacts the expression and function of essential coagulation factors, platelet activation pathways, and endothelial integrity, ultimately shaping hemostatic balance and vascular homeostasis. At the molecular level, GATA-1 regulates the expression of tissue factor (TF), a crucial initiator of the extrinsic coagulation pathway, which plays a central role in thrombin generation and subsequent

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63

fibrin formation. Dysregulated GATA-1 activity may lead to aberrant TF expression, thereby predisposing individuals to a hypercoagulable state and increasing the risk of thrombotic events, such as venous thromboembolism (VTE) and arterial thrombosis, in HIV/AIDS. Furthermore, GATA-1 modulates platelet function and activation, key determinants of hemostasis and thrombosis. By influencing the expression of platelet glycoproteins and signaling molecules involved in platelet activation pathways, GATA-1 regulates platelet adhesion, aggregation, and thrombus formation. Dysregulated GATA-1 activity may disrupt platelet function, impairing hemostatic responses and contributing to bleeding disorders or thrombotic complications observed in HIV-infected individuals.

Moreover, GATA-1 plays a critical role in maintaining endothelial integrity and vascular homeostasis, which are essential for proper coagulation regulation. GATA-1 regulates the expression of von Willebrand factor (vWF), an adhesive glycoprotein crucial for platelet adhesion and thrombus formation at sites of vascular injury. Additionally, GATA-1 influences endothelial cell function and barrier integrity, modulating vascular tone, permeability, and inflammation, which further impact coagulation cascade regulation. The dysregulation of GATA-1-mediated coagulation regulation contributes to the pathogenesis of thrombotic and bleeding complications observed in HIV-infected individuals. By unraveling the intricate interplay between GATA-1 and the coagulation cascade, novel therapeutic targets may be identified to mitigate these hematological complications and improve clinical outcomes in affected individuals. Therapeutic interventions targeting GATA-1-mediated pathways may restore coagulation homeostasis, reduce thrombotic risk, and enhance hemostatic responses in HIV/AIDS, thereby addressing a critical aspect of disease management.<sup>71-100</sup>

### **Thrombotic Complications**

Thrombotic complications, including venous thromboembolism (VTE) and arterial thrombosis, are significant contributors to morbidity and mortality in individuals with Human Immunodeficiency Virus (HIV) infection. Dysregulated coagulation cascade, influenced by factors such as dysregulated GATA-1 activity, predisposes HIV-infected individuals to a prothrombotic state, leading to increased thrombotic risk. Venous thromboembolism, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common thrombotic complication in HIV/AIDS. Factors such as endothelial dysfunction, inflammation, and immobility contribute to the increased risk of VTE in HIV-infected individuals. Dysregulated GATA-1 activity may exacerbate this risk by promoting the expression of tissue factor (TF) and enhancing platelet activation, thereby promoting thrombin generation and fibrin formation.<sup>101-110</sup>

Arterial thrombosis, including myocardial infarction (MI), stroke, and peripheral arterial thrombosis, is another significant thrombotic complication observed in HIV/AIDS. Chronic inflammation, immune activation, and endothelial dysfunction contribute to the increased risk of arterial thrombosis in HIV-infected individuals. Dysregulated GATA-1 activity may further exacerbate this risk by promoting a procoagulant state and impairing fibrinolysis, thereby

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. Elite Journal of Health Science, 2024; 2(3):45-63

increasing the likelihood of thrombotic events in affected individuals. Furthermore, the presence of traditional cardiovascular risk factors, such as smoking, dyslipidemia, and diabetes, coupled with HIV-specific factors, including antiretroviral therapy (ART) and chronic viral replication, further increase the risk of thrombotic complications in this population. Additionally, the prevalence of comorbidities, such as opportunistic infections and malignancies, may contribute to the thrombotic burden in HIV-infected individuals. Thrombotic complications pose significant challenges in the management of HIV/AIDS, requiring a multidisciplinary approach to risk assessment, prevention, and treatment. Anticoagulant therapy, such as low molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs), is often used for the management of acute thrombotic events in HIV-infected individuals. However, the optimal duration and intensity of anticoagulation remain areas of ongoing research and debate. Moreover, efforts to address modifiable risk factors, such as smoking cessation, optimization of ART, and management of comorbidities, are essential for reducing the thrombotic burden in HIV/AIDS. Additionally, further research is needed to elucidate the specific mechanisms underlying thrombotic complications in HIV-infected individuals and to identify novel therapeutic targets for prevention and treatment. By addressing thrombotic complications, clinicians can improve outcomes and quality of life for individuals living with HIV/AIDS.<sup>111-140</sup>

## Bleeding Disorders

Bleeding disorders, including thrombocytopenia and acquired hemophilia, represent significant hematological complications in individuals with Human Immunodeficiency Virus (HIV) infection. Dysregulated coagulation cascade, influenced by factors such as dysregulated GATA-1 activity, predisposes HIV-infected individuals to bleeding tendencies, ranging from mild mucocutaneous bleeding to life-threatening hemorrhage. Thrombocytopenia, characterized by reduced platelet counts, is a common bleeding disorder observed in HIV/AIDS. Multiple factors contribute to thrombocytopenia in HIV-infected individuals, including immune-mediated destruction of platelets, impaired megakaryopoiesis, and medication-related effects. Dysregulated GATA-1 activity may further exacerbate thrombocytopenia by impairing megakaryocyte development and platelet function, thereby increasing the risk of bleeding events in affected individuals. Acquired hemophilia, although less common, is a potentially life-threatening bleeding disorder characterized by the development of autoantibodies against coagulation factor VIII (FVIII). The pathogenesis of acquired hemophilia in HIV/AIDS is multifactorial, involving immune dysregulation, autoantibody production, and impaired clearance of FVIII. Dysregulated GATA-1 activity may contribute to acquired hemophilia by altering the expression and function of coagulation factors, thereby disrupting the balance between procoagulant and anticoagulant pathways and predisposing individuals to bleeding complications.<sup>141-160</sup>

The management of bleeding disorders in HIV/AIDS requires a comprehensive approach, including identification and treatment of underlying causes, supportive care, and targeted interventions to mitigate bleeding risk. For thrombocytopenia, treatment strategies may include platelet transfusions, immunosuppressive therapy, and management of contributing factors such

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63

as opportunistic infections or medication-related effects. For acquired hemophilia, treatment typically involves the administration of bypassing agents, such as recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrates (aPCCs), to control acute bleeding episodes, along with immunosuppressive therapy to suppress autoantibody production. Moreover, efforts to optimize antiretroviral therapy (ART), manage comorbidities, and address modifiable risk factors are essential for reducing the risk of bleeding complications in HIV/AIDS. Additionally, further research is needed to elucidate the specific mechanisms underlying bleeding disorders in HIV-infected individuals and to identify novel therapeutic targets for prevention and treatment. By addressing bleeding disorders, clinicians can improve outcomes and quality of life for individuals living with HIV/AIDS.<sup>161-170</sup>

### **Therapeutic Implications**

The dysregulation of GATA-1 activity in thrombotic and bleeding disorders associated with HIV infection presents therapeutic implications that may offer novel strategies for managing these hematological complications and improving clinical outcomes in affected individuals. Therapeutic interventions aimed at modulating GATA-1 activity hold promise for restoring hematopoietic homeostasis and mitigating thrombotic and bleeding complications in HIV-infected individuals. Small molecule inhibitors, gene editing technologies, and immunomodulatory therapies targeting GATA-1 activity may normalize platelet function, restore coagulation balance, and improve hemostatic responses. By restoring GATA-1-mediated hematopoietic regulation, these therapeutic interventions may reduce thrombotic risk and bleeding tendencies in affected individuals. For individuals with thrombocytopenia, platelet transfusions and hemostatic support are essential for managing bleeding complications and preventing hemorrhagic events. However, given the potential risks associated with platelet transfusions, including transfusion reactions and alloimmunization, alternative strategies such as thrombopoietin receptor agonists may be considered to stimulate platelet production and enhance hemostasis in thrombocytopenic individuals.<sup>171-180</sup>

Anticoagulant therapy plays a crucial role in the management of thrombotic complications in HIV-infected individuals. Direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH) are commonly used for the treatment and prevention of venous thromboembolism (VTE) in this population. However, careful consideration of bleeding risk, drug interactions, and comorbidities is essential when initiating anticoagulant therapy in HIV-infected individuals. In individuals with acquired hemophilia, immunosuppressive therapy is often required to suppress autoantibody production and control bleeding episodes. Corticosteroids, rituximab, and cyclophosphamide are among the immunosuppressive agents used to induce remission and restore coagulation factor levels in affected individuals. Close monitoring of coagulation parameters and adjustment of immunosuppressive therapy are essential for optimizing treatment outcomes and minimizing adverse effects. Given the complex nature of thrombotic and bleeding disorders in HIV-infected individuals, a multidisciplinary approach involving hematologists, infectious disease specialists, and other healthcare providers is essential for comprehensive management. Close

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63



monitoring of coagulation parameters, assessment of bleeding and thrombotic risk factors, and individualized treatment strategies are essential for optimizing therapeutic outcomes and improving clinical outcomes in affected individuals.<sup>181-182</sup>

## Conclusion

GATA-1 plays a critical role in regulating the coagulation cascade and endothelial function in HIV-associated hematological complications. Dysregulated GATA-1 activity contributes to thrombotic and bleeding complications observed in HIV-infected individuals, highlighting its significance in disease pathogenesis. Therapeutic targeting of GATA-1-mediated pathways offers potential avenues for managing hematological complications in HIV/AIDS and improving clinical outcomes in affected individuals. Further research is warranted to elucidate the specific mechanisms underlying GATA-1 regulation of the coagulation cascade and to evaluate the safety and efficacy of GATA-1-targeted therapies in clinical settings.

## References

1. Mann Z, Sengar M, Verma YK, Rajalingam R, Raghav PK. Hematopoietic stem cell factors: their functional role in self-renewal and clinical aspects. *Frontiers in Cell and Developmental Biology*. 2022; 10:664261.
2. Sezaki M, Hayashi Y, Wang Y, Johansson A, Umemoto T, Takizawa H. Immunomodulation of hematopoietic stem and progenitor cells in inflammation. *Frontiers in immunology*. 2020; 11:585367.
3. Okeke C, Silas U, Okeke C, Chikwendu C. Current trends on hemopoietic stem cells. *Current Stem Cell Research & Therapy*. 2021;16(2):199-208.
4. Lee J, Yoon SR, Choi I, Jung H. Causes and mechanisms of hematopoietic stem cell aging. *International Journal of Molecular Sciences*. 2019;20(6):1272.
5. Govindarajah V, Reynaud D. Tuning of the hematopoietic stem cell compartment in its inflammatory environment. *Current stem cell reports*. 2018; 4:189-200.
6. Abunimye DA, Okafor IM, Okorowo H, Obeagu EI. The role of GATA family transcriptional factors in haematological malignancies: A review. *Medicine*. 2024;103(12):e37487.
7. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. *Int. J. Curr. Res. Med. Sci*. 2018;4(10):42-8.
8. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. *Int. J. Adv. Res. Biol. Sci*. 2015;2(7):58-62.
9. Ifeanyi OE. Acute Leukaemia: A Sudden Killer to Human Beings. *EC Emergency Medicine and Critical Care*. 2020;4(6):154-67.
10. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63

11. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
12. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
13. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
14. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
15. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
16. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
17. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
18. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
19. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
20. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
21. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.  
[https://www.academia.edu/download/38320140/Obeagu\\_Emmanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. Elite Journal of Health Science, 2024; 2(3):45-63

22. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
23. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.iosrjournals.org/ViewArticle.aspx?doi=5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf)
24. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):110-119.
25. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.researchgate.net/publication/311111111/links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).
26. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://www.researchgate.net/publication/3645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf).
27. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144. [https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJC\\_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
28. Obimah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.researchgate.net/publication/330555555/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
29. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](https://doi.org/10.22192/ijcrms.2017.03.02.005)
30. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63



31. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://doi.org/10.24015/EJMS.2023.139).
32. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
33. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
34. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
35. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.24015/EJMS.2022.137).
36. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 [https://www.academia.edu/download/54317126/Haematological\\_indices\\_of\\_malaria\\_patients\\_coinfected\\_with\\_HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. Elite Journal of Health Science, 2024; 2(3):45-63

40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).
41. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
42. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
43. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Sтивен PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
44. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
45. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):42-57. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
46. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
47. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
48. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160. [links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://doi.org/10.32474/JCCM.2020.02.000137links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. Elite Journal of Health Science, 2024; 2(3):45-63

49. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
50. Lionberger JM, Stirewalt DL. Gene expression changes in normal haematopoietic cells. *Best Practice & Research Clinical Haematology.* 2009;22(2):249-269.
51. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: [10.22192/ijcrps.2019.06.12.004links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://doi.org/10.22192/ijcrps.2019.06.12.004links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
52. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.002links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
53. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://doi.org/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
54. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910. [https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
55. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
56. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
57. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
58. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharma Research.* 2014; 391:186-189.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63

59. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
60. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
61. Alvarez F, Fritz JH, Piccirillo CA. Pleiotropic effects of IL-33 on CD4+ T cell differentiation and effector functions. *Frontiers in immunology*. 2019; 10:438556.
62. Chirumbolo S, Bjørklund G, Sboarina A, Vella A. The role of basophils as innate immune regulatory cells in allergy and immunotherapy. *Human vaccines & immunotherapeutics*. 2018;14(4):815-831.
63. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemima MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
64. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
65. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
66. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
67. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
68. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
69. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
70. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
71. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63

72. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46):e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
73. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
74. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
75. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
76. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
77. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
78. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024;103(9): e37354.
79. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
80. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
81. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
82. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
83. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>*;12(01).
84. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
85. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>*;12(01).
86. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
87. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
88. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
89. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63



90. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
91. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
92. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
93. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
94. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
95. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
96. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
97. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
98. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
99. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: <http://www.journalijar.com>;12(01).
100. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
101. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
102. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
103. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
104. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
105. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
106. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63

107. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.
108. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
109. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
110. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*. 2024;2(2):60-73.
111. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
112. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*. 2024;2(2):33-46.
113. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):11-24.
114. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
115. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology*. 2024;2(3):33-44.
116. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
117. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: <http://www.journalijar.com>;12(01)*.
118. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;12(01)*.
119. Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in Confronting HIV Stigma. *Elite Journal of Public Health*. 2024;2(3):22-36.
120. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
121. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
122. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63

123. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
124. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
125. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):41-51.
126. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
127. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*. 2024;2(3):1-8.
128. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
129. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2 (3):42-57.
130. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*. 2024;2(1):1-6.
131. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
132. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
133. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*. 2024;2(2):16-29.
134. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
135. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science*. 2024;2(2):1-7.
136. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
137. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
138. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):42-60.
139. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-5.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63

140. Obeagu EI, Obeagu GU, Odo EO, Igwe MC, Ugwu OP, Alum EU, Racheal P. Combatting Stigma: Essential Steps in Halting HIV Spread. IAA Journal of Applied Sciences. 2024;11(1):22-9.
141. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2 (3):25-41.
142. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
143. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV. 2024;2(2):43-59.
144. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science. 2024;2(3):23-35.
145. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
146. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):84-99.
147. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science. 2024;2(2):20-35.
148. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine. 2024;2(2):30-46.
149. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
150. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health. 2024;2(1):35-51.
151. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. Elite Journal of Medicine. 2024;2(3):48-59.
152. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology. 2024;2(2):43-59.
153. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):14-32.
154. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review. 2024;2(1):17-41.

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. Elite Journal of Health Science, 2024; 2(3):45-63

155. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.
156. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*, 2024; 2(3):111-7.
157. Obeagu EI, Obeagu GU. Anemia in HIV: The Role of Erythropoietin in Disease Progression. *Elite Journal of Haematology*, 2024; 2(4): 51-67
158. Obeagu EI, Obeagu GU. **ART and Platelet Dynamics: Assessing Implications for HIV Patient Care.** *Elite Journal of Haematology*, 2024; 2(4): 68-85
159. Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV. *Elite Journal of Nursing and Health Science*, 2024; 2(4):23-39
160. Obeagu EI, Obeagu GU. HIV-Induced Immune Exhaustion in Neonates: A Review of Mechanisms and Implications. *Elite Journal of Immunology*, 2024; 2(3): 45-61
161. Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. *Elite Journal of Immunology*, 2024; 2(3): 62-79
162. Obeagu EI, Obeagu GU. Hematological Consequences of Erythropoietin in HIV: Clinical Implications. *Elite Journal of Haematology*, 2024; 2(4): 86-104
163. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Dysfunction in HIV-Related Hematological Malignancies: A Review. *Elite Journal of Haematology*, 2024; 2(4): 105-122
164. Obeagu EI, Obeagu GU. Exploration of Intricate Relationship between GATA-1 and Anemia in HIV. *Elite Journal of Haematology*, 2024; 2(4): 123-140
165. Obeagu EI, Obeagu GU. GATA-1 and Immune Dysregulation in HIV/AIDS: Implications for Therapy. *Elite Journal of HIV*, 2024; 2(3): 69-85
166. Obeagu EI, Obeagu GU. The Role of GATA-1 in Erythropoietin Response and Resistance in HIV/AIDS. *Elite Journal of HIV*, 2024; 2(4): 1-17
167. Obeagu EI, Obeagu GU. Understanding the Role of GATA-1 in T-Cell Development in the Context of HIV Infection. *Elite Journal of HIV*, 2024; 2(4): 18-34
168. Obeagu EI, Obeagu GU. Programmed Cell Death Protein 1 (PD-1) Pathway Modulation in HIV/AIDS: From Bench to Bedside. *Elite Journal of HIV*, 2024; 2(4): 35-53
169. Obeagu EI, Obeagu GU. Programmed Cell Death Protein 1 (PD-1) and Immune Checkpoint Inhibitors in HIV-Related Lymphomas: Current Insights and Future Directions. *Elite Journal of Immunology*, 2024; 2(4): 1-17
170. Obeagu EI, Obeagu, GU. Programmed Cell Death Protein 1 (PD-1) Signaling in HIV-Associated Cardiovascular Disease: Mechanisms and Therapeutic Implications. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 61-77
171. Obeagu EI, Obeagu, GU. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade and HIV-Associated Kaposi Sarcoma: A Promising Therapeutic Strategy. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 78-94

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63



172. Obeagu EI, Obeagu GU. The Impact of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Genetic Variations on HIV Susceptibility and Progression. *Elite Journal of Immunology*, 2024; 2(4): 18-35
173. Obeagu EI, Obeagu, GU. Antacid Use in HIV Patients: Implications for Drug Absorption, Metabolism, and Adverse Effects. *Elite Journal of Scientific Research and Review*, 2024; 2(3): 1-19
174. Obeagu EI, Obeagu GU. Erythropoietin Signaling and its Implications in HIV-Related Anemia: A Comprehensive Review. *Elite Journal of HIV*, 2024; 2(4): 54-71
175. Obeagu EI, Obeagu, GU. The Role of GATA-1 in Megakaryocyte Function and Platelet Production During HIV Infection: A Review. *Elite Journal of Scientific Research and Review*, 2024; 2(3): 20-36
176. Obeagu EI, Obeagu GU. GATA-1 and Bone Marrow Failure Syndromes in the Context of HIV Infection: A Review of Molecular Mechanisms and Therapeutic Implications. *Elite Journal of Laboratory Medicine*, 2024; 2(3): 39-56
177. Obeagu EI, Obeagu GU. GATA-1 Mutations and Their Association with HIV-Associated Hematological Disorders: A Review. *Elite Journal of Health Science*, 2024; 2(4): 7-23
178. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Maintenance in HIV: Mechanisms and Implications. *Elite Journal of Health Science*, 2024; 2(4): 24-40
179. Obeagu EI, Obeagu GU. GATA-1 Regulation of Erythroid Progenitor Cell Differentiation in HIV/AIDS: Molecular Insights and Therapeutic Implications. *Elite Journal of Haematology*, 2024; 2(4): 141-159
180. Obeagu EI, Obeagu GU. Role of GATA-1 in Megakaryopoiesis and Thrombopoiesis During HIV Infection: Molecular Insights and Therapeutic Implications. *Elite Journal of Nursing and Health Science*, 2024; 2(4):40-59
181. Obeagu EI, Obeagu GU. GATA-1 as a Modulator of Immune Responses in HIV-Infected Individuals: Implications for Disease Pathogenesis and Therapeutic Interventions. *Elite Journal of Laboratory Medicine*, 2024; 2(3): 57-74
182. Obeagu EI, Obeagu GU. GATA-1 and Inflammatory Signaling Pathways in HIV-Related Hematological Disorders: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):27-44

**Citation:** Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63